Cancer and atrial fibrillation: Epidemiology, mechanisms, and anticoagulation treatment

被引：26

作者：

Menichelli, Danilo ^{[1
]}

Vicario, Tommasa ^{[2
,3
]}

Ameri, Pietro ^{[4
,6
]}

Toma, Matteo ^{[4
,6
]}

Violi, Francesco ^{[1
,5
]}

Pignatelli, Pasquale ^{[1
,5
]}

Pastori, Daniele ^{[1
]}

机构：

[1] Sapienza Univ Rome, Dept Clin Internal Anesthesiol & Cardiovasc Sci, Rome, Italy

[2] Sapienza Univ Rome, Dept Gen Surg & Surg Specialties Paride Stefanini, Rome, Italy

[3] Policlin Tor Vergata Hosp, Emergency Dept, Rome, Italy

[4] IRCCS Osped Policlin San Martino, Cardiovasc Dis Unit, Genoa, Italy

[5] Mediterranea Cardioctr, Naples, Italy

[6] Univ Genoa, Dept Internal Med, Genoa, Italy

来源：

PROGRESS IN CARDIOVASCULAR DISEASES | 2021年 / 66卷

关键词：

Atrial fibrillation; Cancer; Oral anticoagulants; Chemotherapy; Radiotherapy; DOACs; DIRECT ORAL ANTICOAGULANTS; OXIDATIVE STRESS; RISK-FACTORS; CARDIOVASCULAR TOXICITY; POSITION PAPER; 2016; ESC; WARFARIN; SAFETY; THROMBOCYTOPENIA; THROMBOEMBOLISM;

D O I：

10.1016/j.pcad.2021.04.004

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

Cancer patients are at an increased risk of developing atrial fibrillation (AF) and thrombosis. However, the management of anticoagulation in patients with both diseases may be challenging, and data on these patients are lacking. We summarize the current evidence on the incidence and prevalence of cancer in AF and vice versa and provide some practical considerations on the management of oral anticoagulation in specific clinical situations. Low-molecular weight heparins are not approved for thromboprophylaxis in AF, and management of warfarin can be difficult. The use of direct oral anticoagulants may be particularly attractive for their rapid onset/ offset action and lower bleeding risk. (c) 2021 Elsevier Inc. All rights reserved.

引用

页码：28 / 36

页数：9

共 50 条

[31] Pericardial fat and atrial fibrillation: Epidemiology, mechanisms and interventions
Al-Rawahi, Mohamed
Proietti, Riccardo
Thanassoulis, George
INTERNATIONAL JOURNAL OF CARDIOLOGY, 2015, 195 : 98 - 103
[32] Obesity, Diabetes and Atrial Fibrillation; Epidemiology, Mechanisms and Interventions
Asghar, O.
Alam, U.
Hayat, S. A.
Aghamohammadzadeh, R.
Heagerty, A. M.
Malik, R. A.
CURRENT CARDIOLOGY REVIEWS, 2012, 8 (04) : 253 - 264
[33] Anticoagulation Treatment and Management in Hemodialysis Patients with Atrial Fibrillation
Rao, Sapna
Kshirsagar, Abhijit V.
Layton, J. Bradley
Brookhart, M. Alan
PHARMACOEPIDEMIOLOGY AND DRUG SAFETY, 2017, 26 : 593 - 593
[34] Unsolved issues in oral anticoagulation treatment in atrial fibrillation
Agewall, Stefan
EUROPEAN HEART JOURNAL-CARDIOVASCULAR PHARMACOTHERAPY, 2019, 5 (02) : 60 - 61
[35] CHRONIC ATRIAL-FIBRILLATION - ANTICOAGULATION OR DEFIBRILLATION TREATMENT
KALUSCHE, D
PERFUSION, 1992, 5 (08): : 252 - 253
[36] Treatment of atrial fibrillation in ICU (apart from anticoagulation)
Marque, S.
Launey, Y.
REANIMATION, 2012, 21 (02): : 180 - 187
[37] Anticoagulation therapy in patients with atrial fibrillation and active cancer
Jaakkola, J.
Teppo, K.
Halminen, O.
Linna, M.
Haukka, J.
Putaala, J.
Mustonen, P.
Kinnunen, J.
Hartikainen, J.
Airaksinen, K. E. J.
Lehto, M.
EUROPEAN HEART JOURNAL, 2023, 44
[38] Use of anticoagulation in patients with breast cancer and atrial fibrillation
Sorigue, Marc
BREAST, 2019, 48 : 98 - 98
[39] Patterns of Anticoagulation Use in Patients With Cancer With Atrial Fibrillation and/or Atrial Flutter
Fradley, Michael G.
Ellenberg, Kerry
Alomar, Mohammed
Swanson, Justin
Kharod, Anant
Nguyen, Anh Thy H.
Khodor, Sara
Mishra, Shreya
Duong, Linh M.
Shah, Nirav
Armanious, Merna
Rhea, Isaac B.
Schabath, Matthew B.
Kip, Kevin E.
JACC: CARDIOONCOLOGY, 2020, 2 (05): : 747 - 754
[40] Anticoagulation in Cancer Patients With Atrial Fibrillation or Atrial Flutter Are There Gaps in Care?
Russo, Andrea M.
JACC: CARDIOONCOLOGY, 2020, 2 (05): : 755 - 757

← 1 2 3 4 5 →